Pergolide in late‐stage Parkinson disease
Identifieur interne : 002B15 ( Main/Exploration ); précédent : 002B14; suivant : 002B16Pergolide in late‐stage Parkinson disease
Auteurs : A. E. Lang [Royaume-Uni, Canada] ; N. Quinn [Royaume-Uni] ; S. Brincat [Royaume-Uni] ; C. D. Marsden [Royaume-Uni] ; Parkes [Royaume-Uni]Source :
- Annals of Neurology [ 0364-5134 ] ; 1982-09.
Abstract
Twenty‐six patients with late‐stage Parkinson disease were given 0.4 to 15 mg of pergolide mesylate daily in addition to, or as replacement for, levodopa or bromocriptine therapy. Despite treatment with individually determined optimum doses of levodopa, bromocriptine, and anticholinergics, they had shown response failure or fluctuating response. Forty percent (11 patients) were unable to tolerate pergolide. Nausea and vomiting, somnolence, and psychiatric disturbances were the most frequent side effects. Eleven of the remaining patients improved on pergolide, 2 were unchanged, and 2 were slightly worse. Among the patients who benefited, pergolide improved dose‐related response fluctuations more than non‐dose‐related fluctuations, with a reduction in number and duration of “off” periods and improvement in quality of sleep and early morning akinesia but little change in freezing episodes. Despite treatment failure in many cases, pergolide is at present the best available drug for specific latestage management problems.
Url:
DOI: 10.1002/ana.410120305
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pergolide in late‐stage Parkinson disease</title><author><name sortKey="Lang, A E" sort="Lang, A E" uniqKey="Lang A" first="A. E." last="Lang">A. E. Lang</name></author><author><name sortKey="Quinn, N" sort="Quinn, N" uniqKey="Quinn N" first="N." last="Quinn">N. Quinn</name></author><author><name sortKey="Brincat, S" sort="Brincat, S" uniqKey="Brincat S" first="S." last="Brincat">S. Brincat</name></author><author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name></author><author><name sortKey="Parkes" sort="Parkes" uniqKey="Parkes" last="Parkes">Parkes</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:BE242EEB7060360B7C6EE28770D3AE6CA125B544</idno><date when="1982" year="1982">1982</date><idno type="doi">10.1002/ana.410120305</idno><idno type="url">https://api.istex.fr/document/BE242EEB7060360B7C6EE28770D3AE6CA125B544/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000A80</idno><idno type="wicri:Area/Main/Curation">000944</idno><idno type="wicri:Area/Main/Exploration">002B15</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Pergolide in late‐stage Parkinson disease</title><author><name sortKey="Lang, A E" sort="Lang, A E" uniqKey="Lang A" first="A. E." last="Lang">A. E. Lang</name><affiliation wicri:level="2"><country>Royaume-Uni</country><placeName><region type="country">Angleterre</region></placeName><wicri:cityArea>The University Department of Neurology, Institute of Psychiatry and King's College Hospital, Denmark Hill, London SE5 8AF</wicri:cityArea></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Current Address: Division of Neurology, Toronto Western Hospital, 399 Bathurst St, Toronto, Ont</wicri:regionArea><wicri:noRegion>Ont</wicri:noRegion></affiliation></author><author><name sortKey="Quinn, N" sort="Quinn, N" uniqKey="Quinn N" first="N." last="Quinn">N. Quinn</name><affiliation wicri:level="2"><country>Royaume-Uni</country><placeName><region type="country">Angleterre</region></placeName><wicri:cityArea>The University Department of Neurology, Institute of Psychiatry and King's College Hospital, Denmark Hill, London SE5 8AF</wicri:cityArea></affiliation></author><author><name sortKey="Brincat, S" sort="Brincat, S" uniqKey="Brincat S" first="S." last="Brincat">S. Brincat</name><affiliation wicri:level="2"><country>Royaume-Uni</country><placeName><region type="country">Angleterre</region></placeName><wicri:cityArea>The University Department of Neurology, Institute of Psychiatry and King's College Hospital, Denmark Hill, London SE5 8AF</wicri:cityArea></affiliation></author><author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name><affiliation wicri:level="2"><country>Royaume-Uni</country><placeName><region type="country">Angleterre</region></placeName><wicri:cityArea>The University Department of Neurology, Institute of Psychiatry and King's College Hospital, Denmark Hill, London SE5 8AF</wicri:cityArea></affiliation></author><author><name sortKey="Parkes" sort="Parkes" uniqKey="Parkes" last="Parkes">Parkes</name><affiliation wicri:level="2"><country>Royaume-Uni</country><placeName><region type="country">Angleterre</region></placeName><wicri:cityArea>The University Department of Neurology, Institute of Psychiatry and King's College Hospital, Denmark Hill, London SE5 8AF</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="sub">Official Journal of the American Neurological Association and the Child Neurology Society</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1982-09">1982-09</date><biblScope unit="volume">12</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="243">243</biblScope><biblScope unit="page" to="247">247</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">BE242EEB7060360B7C6EE28770D3AE6CA125B544</idno><idno type="DOI">10.1002/ana.410120305</idno><idno type="ArticleID">ANA410120305</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Twenty‐six patients with late‐stage Parkinson disease were given 0.4 to 15 mg of pergolide mesylate daily in addition to, or as replacement for, levodopa or bromocriptine therapy. Despite treatment with individually determined optimum doses of levodopa, bromocriptine, and anticholinergics, they had shown response failure or fluctuating response. Forty percent (11 patients) were unable to tolerate pergolide. Nausea and vomiting, somnolence, and psychiatric disturbances were the most frequent side effects. Eleven of the remaining patients improved on pergolide, 2 were unchanged, and 2 were slightly worse. Among the patients who benefited, pergolide improved dose‐related response fluctuations more than non‐dose‐related fluctuations, with a reduction in number and duration of “off” periods and improvement in quality of sleep and early morning akinesia but little change in freezing episodes. Despite treatment failure in many cases, pergolide is at present the best available drug for specific latestage management problems.</div></front></TEI><affiliations><list><country><li>Canada</li><li>Royaume-Uni</li></country><region><li>Angleterre</li></region></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Lang, A E" sort="Lang, A E" uniqKey="Lang A" first="A. E." last="Lang">A. E. Lang</name></region><name sortKey="Brincat, S" sort="Brincat, S" uniqKey="Brincat S" first="S." last="Brincat">S. Brincat</name><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name><name sortKey="Parkes" sort="Parkes" uniqKey="Parkes" last="Parkes">Parkes</name><name sortKey="Quinn, N" sort="Quinn, N" uniqKey="Quinn N" first="N." last="Quinn">N. Quinn</name></country><country name="Canada"><noRegion><name sortKey="Lang, A E" sort="Lang, A E" uniqKey="Lang A" first="A. E." last="Lang">A. E. Lang</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B15 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002B15 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:BE242EEB7060360B7C6EE28770D3AE6CA125B544
|texte= Pergolide in late‐stage Parkinson disease
}}
| This area was generated with Dilib version V0.6.23. |  |